Clinical Trial

Phase IIa Study for IPG11406 in Patients With Lupus Nephritis

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated January 13, 2026 (before its estimated April 22, 2026 completion). Its status may not reflect the trial's current state.
Summary
A multi-center, multi-dose phase Ib/IIa clinical study evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics, and impact on biomarkers of IPG11406 in patients with Lupus Nephritis
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-11-30; most recent amendment 2026-01-12.
Status change: Not Yet Recruiting → Recruiting 2025-02-06
Trial Details
NCT Number NCT06717815
Lead Sponsor Nanjing Immunophage Biotech Co., Ltd
Conditions Lupus Nephritis
Enrollment 36 participants
Start Date 2025-02-25
Primary Completion 2026-04-22 (estimated)
Study Completion 2026-04-22 (estimated)
Updated on ClinicalTrials.gov 2026-01-13